☆ 4.7 Article

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

RHEUMATOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Rheumatology

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

Charlotte L. M. Krieckaert et al.

Summary: This study develops EULAR points-to-consider for therapeutic drug monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases (RMDs). The points-to-consider are evidence-based and consensus-based statements that highlight the clinical utility of TDM. However, the lack of high quality trials addressing effectiveness and safety of TDM, as well as robust economic evaluation, limits its wider adoption.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Rheumatology

Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritis

Ryan M. Hum et al.

Summary: This study suggests that higher levels of TNF-a inhibitor serum drug levels (SDLs) are associated with good treatment response in fully adherent patients. Interventions to improve SDLs, such as encouraging adherence, may improve treatment response. The identified SDL cut-offs for adalimumab and certolizumab may be useful in clinical practice.

RHEUMATOLOGY (2023)

Add to Collection

Article Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S. Smolen et al.

Summary: This study provides an update on the management recommendations for rheumatoid arthritis (RA) based on the latest developments in the field. The recommendations cover various aspects including medication use, combination therapy, treatment strategies, and dose reduction. The consensus was reached on 5 overarching principles and 11 specific recommendations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Add to Collection

Article Gastroenterology & Hepatology

Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives

Peter M. Irving et al.

Summary: Therapeutic drug monitoring (TDM) is an optimization strategy in the treatment of inflammatory bowel diseases, aiming to achieve maximal treatment benefits by monitoring drug concentrations. There are variations in optimal drug concentrations based on treatment targets, disease phenotypes, inflammatory burden, and sampling timing. This review discusses the role of TDM in biologic and oral small molecule therapies, the differences between reactive and proactive TDM, and the areas where evidence is lacking. Future adaptations in TDM usage may contribute to personalized treatment for patients with IBD.

GASTROENTEROLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Risk factors for anti-drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial

Marthe Kirkesaether Brun et al.

Summary: This study identified several risk factors for the formation of anti-drug antibodies (ADAb) during early-phase infliximab treatment. Factors such as a diagnosis of rheumatoid arthritis, lifetime smoking, concomitant immunosuppressors, and a diagnosis of spondyloarthritis were associated with increased or reduced risk of ADAb formation. Additionally, higher disease activity and longer drug holidays increased the risk, while higher doses and serum concentrations of infliximab reduced the risk of immunogenicity.

JOURNAL OF INTERNAL MEDICINE (2022)

Add to Collection

News Item Biotechnology & Applied Microbiology

Top companies and drugs by sales in 2021

Lisa Urquhart

NATURE REVIEWS DRUG DISCOVERY (2022)

Add to Collection

Review Rheumatology

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider

Charlotte Krieckaert et al.

Summary: The objective of this review is to collect and summarize evidence on therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases. The review found that there is evidence to support the use of TDM in some clinical scenarios, but not enough to support routine implementation.

RMD OPEN (2022)

Add to Collection

Review Oncology

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Johanna Elin Gehin et al.

Summary: Biologic drugs have significantly improved the outcomes of inflammatory joint diseases but many patients do not respond or lose response to the treatment. The formation of anti-drug antibodies (ADAb) poses a clinical problem as it affects the pharmacokinetics of the drug and reduces its clinical efficacy. Therapeutic drug monitoring, which measures ADAb and serum drug concentrations, has been suggested to optimize therapy with biologic drugs. However, there are challenges and difficulties in comparing results between different assays and laboratories, and limited data supports therapeutic drug monitoring as a routine strategy in clinical practice.

BIODRUGS (2022)

Add to Collection

Review Oncology

Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab

Rodrigo Borrega et al.

Summary: This study identified significant variability in the reported immunogenicity rates of adalimumab across different studies, with a noticeable increase over time. The type of assay used to detect anti-adalimumab antibodies, as well as the study type and exposure time, were found to be associated with the immunogenicity rates. Factors contributing to the temporal increase in immunogenicity rates require further investigation in future studies.

BIODRUGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective

Pekka Kurki et al.

Summary: This study analyzed the safety and interchangeability data of biosimilar mAbs and fusion proteins, demonstrating comparable efficacy, safety, and immunogenicity compared with the reference products. Postmarketing surveillance data did not reveal any biosimilar-specific adverse effects, indicating no need for additional systematic switch studies to support patient switching.

DRUGS (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases A Randomized Clinical Trial

Silje Watterdal Syversen et al.

Summary: This study demonstrates that proactive therapeutic drug monitoring (TDM) is more effective than standard therapy in maintaining disease control and preventing disease worsening among patients with immune-mediated inflammatory diseases undergoing maintenance therapy with infliximab. Further research is needed to compare proactive TDM with reactive TDM and evaluate the cost-effectiveness of this approach.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Gastroenterology & Hepatology

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber et al.

Summary: This study demonstrated the pharmacokinetic noninferiority of CT-P13 SC to CT-P13 IV, with comparable clinical remission rates between the two formulations.

GASTROENTEROLOGY (2021)

Add to Collection

Article Rheumatology

Association of Pharmacological Biomarkers with Treatment Response and Longterm Disability in Patients with Psoriatic Arthritis: Results from OUTPASS

Meghna Jani et al.

JOURNAL OF RHEUMATOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Early Adalimumab and Anti-Adalimumab Antibody Levels for Prediction of Primary Nonresponse in Ankylosing Spondylitis Patients

Xiaoliang Ding et al.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)

Add to Collection

Editorial Material Rheumatology

An Opportunity Missed: Biosimilars in the United States

Guro L. Goll et al.

ARTHRITIS & RHEUMATOLOGY (2020)

Add to Collection

Article Immunology

What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?

Puja Mehta et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Rheumatology

Discontinuation of biologic therapy due to lack/loss of response and adverse events is similar between TNFi and non-TNFi class: Results from a real-world rheumatoid arthritis cohort

Mohammad Movahedi et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)

Add to Collection

Article Rheumatology

Clinical relevance of monitoring serum adalimumab levels in axial spondyloarthritis

Jose Miguel Senabre Gallego et al.

RHEUMATOLOGY INTERNATIONAL (2019)

Add to Collection

Article Gastroenterology & Hepatology

Prospective Observational Evaluation of Time-Dependency of Adalimumab Immunogenicity and Drug Concentrations: The POETIC Study

Bella Ungar et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)

Add to Collection

Article Dermatology

Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches

A. Blauvelt et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

Add to Collection

Article Pharmacology & Pharmacy

Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial

Sandra L. Goss et al.

CLINICAL THERAPEUTICS (2018)

Add to Collection

Article Rheumatology

Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?

Brigitte Michelsen et al.

ANNALS OF THE RHEUMATIC DISEASES (2018)

Add to Collection

Review Oncology

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review

Vibeke Strand et al.

BIODRUGS (2017)

Add to Collection

Article Rheumatology

Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score

Monika M. Schoels et al.

ANNALS OF THE RHEUMATIC DISEASES (2016)

Add to Collection

Letter Rheumatology

Search for a concentration-effect curve of adalimumab in ankylosing spondylitis patients

A. F. Marsman et al.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2016)

Add to Collection

Review Oncology

Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis

Sarah S. Thomas et al.

BIODRUGS (2015)

Add to Collection

Article Rheumatology

Clinical Utility of Random Anti-Tumor Necrosis Factor Drug-Level Testing and Measurement of Antidrug Antibodies on the Long-Term Treatment Response in Rheumatoid Arthritis

Meghna Jani et al.

ARTHRITIS & RHEUMATOLOGY (2015)

Add to Collection

Article Rheumatology

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

C. L. M. Krieckaert et al.

ANNALS OF THE RHEUMATIC DISEASES (2015)

Add to Collection

Article Rheumatology

Key findings towards optimising adalimumab treatment: the concentration-effect curve

Mieke F. Pouw et al.

ANNALS OF THE RHEUMATIC DISEASES (2015)

Add to Collection

Article Rheumatology

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial

Gerd-Rudiger Burmester et al.

ANNALS OF THE RHEUMATIC DISEASES (2015)

Add to Collection

Letter Rheumatology

Towards an individualised target concentration of adalimumab in rheumatoid arthritis

Emilie Ducourau et al.

ANNALS OF THE RHEUMATIC DISEASES (2014)

Add to Collection

Article Rheumatology

Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up

Erik H. Vogelzang et al.

ANNALS OF THE RHEUMATIC DISEASES (2014)

Add to Collection

Article Rheumatology

Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation

Jacqueline E. Paramarta et al.

ARTHRITIS RESEARCH & THERAPY (2014)

Add to Collection

Review Rheumatology

Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers

Anamika Arora et al.

INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2013)

Add to Collection

Letter Rheumatology

Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner

Charlotte L. Krieckaert et al.

ANNALS OF THE RHEUMATIC DISEASES (2012)

Add to Collection

Article Rheumatology

Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores

Pedro Machado et al.

ANNALS OF THE RHEUMATIC DISEASES (2011)

Add to Collection

Article Medicine, General & Internal

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

Geertje M. Bartelds et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.